Pause all of them in the 48-hour-before and 72-hour-after window
It mainly affects peoples central vision, which means they have a challenging time seeing in front of them, but their peripheral vision is intact, according to the National Institutes of Health (NIH)
As evidence evolves, many providers are reconsidering which therapies deliver both glycemic control and cardiovascular Read More GLP-1 Resistance in Clinical Practice: What New Genetic Insights May Explain Apr 20, 2026 Articles, Diabetes, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Type 2 Diabetes, Type 2 Diabetes 4,759 views Why do some patients respond dramatically to GLP-1 therapies while others see little benefit
Oral versions are going to be the big game changer, he said
Beyond BMI: Alternative Metrics for Immunotherapy Response Recently, research has been focusing on finding more accurate alternative tools to BMI in order to explain the obesity paradox